Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Daniel Johns

Pain Medicine Cincinnati, OH Medical Doctor

NPI 1376907782 CMS profile 8803789

379 Dixmyth Ave, Cincinnati, OH 45220

Open in the dashboard

General payments

$21,681

59 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Johns of Cincinnati, OH is reported in the CMS Open Payments database as having received $21,681 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $364 14
2024 General $460 5
2023 General $300 14
2022 General $225 10
2021 General $186 10
2020 General $20,147 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Johns
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Daniel Johns were reported at $364. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Daniel Johns Pain Medicine median Middle half National median
2019 $0 $506 $144–$1,566 $163
2020 $20,147 $315 $96–$934 $114
2021 $186 $452 $134–$1,237 $132
2022 $225 $475 $124–$1,407 $149
2023 $300 $480 $136–$1,384 $160
2024 $460 $521 $164–$1,511 $164
2025 $364 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Boston Scientific Corporation $20,691 18 payments
  2. Abbott Laboratories $144 1 payment
  3. Relievant Medsystems, Inc. $126 3 payments
  4. Nevro Corp. $118 6 payments
  5. Medtronic, Inc. $96 4 payments
  6. AbbVie, Inc. $64 3 payments
  7. Globus Medical, Inc. $53 2 payments
  8. Biodelivery Sciences International, Inc. $43 3 payments
  9. RedHill Biopharma Inc. $42 2 payments
  10. IBSA Pharma Inc. $36 2 payments
  11. Other $269 15 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $20,000 1 payment
  2. Food and Beverage $1,681 58 payments
Products named General payments · program years 2020–2025
  1. SPECTRA WAVEWRITER $20,009 2 payments
  2. WaveWriter Alpha Prime 16 $345 8 payments
  3. ETERNA $144 1 payment
  4. Intracept Pain $126 3 payments
  5. Intracept Pain $81 2 payments
  6. Intracept Pain $81 2 payments
  7. Intracept Pain $81 2 payments
  8. SUPERION $81 1 payment
  9. Omnia $67 3 payments
  10. INTELLIS ADAPTIVESTIM $58 2 payments
  11. Other $752 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,882

Median for Pain Management: 951

Drug cost

$34,167

Median for Pain Management: $26,034

Branded share of claims

26.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 324 $4,884
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 294 $4,372
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 191 $4,180
Pregabalin Generic 152 $3,774
Buprenorphine Generic 23 $3,561
Lidocaine Generic 28 $2,071
Celecoxib Generic 46 $1,937
Methocarbamol Generic 101 $1,422
Naloxone Hcl Generic 25 $1,405
Duloxetine Hcl Generic 89 $1,279

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$117,342

Of which drugs: $20,995

Medicare patients

296

Average age 74

Services billed

9,116

173 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 39%
Diabetes 34%
Chronic kidney disease 30%
Depression 29%
Osteoporosis 27%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 227 $167

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record